Background: The pre-surgical evaluation for drug-resistant epilepsy achieves seizure freedom in only 50-60% of patients. Efforts to identify quantitative intracranial EEG (qEEG) biomarkers of epileptogenicity are needed. This review summarizes and evaluates the design of qEEG studies, discusses barriers to biomarker adoption, and proposes refinements of qEEG study protocols.
View Article and Find Full Text PDFIntroduction: Epilepsy surgery is the only curative treatment for patients with drug-resistant focal epilepsy. Stereoelectroencephalography (SEEG) is the gold standard to delineate the seizure-onset zone (SOZ). However, up to 40% of patients are subsequently not operated as no focal non-eloquent SOZ can be identified.
View Article and Find Full Text PDFBackground: Ictal stereo-encephalography (sEEG) biomarkers for seizure onset zone (SOZ) localization can be classified depending on whether they target abnormalities in signal power or functional connectivity between signals, and they may depend on the frequency band and time window at which they are estimated.
New Method: This work aimed to compare and optimize the performance of a power and a connectivity-based biomarker to identify SOZ contacts from ictal sEEG recordings. To do so, we used a previously introduced power-based measure, the normalized mean activation (nMA), which quantifies the ictal average power activation.
Objective: Stereo-electroencephalography (SEEG)-guided radiofrequency thermocoagulation (RFTC) is being used incrementally in the invasive diagnosis of epilepsy. There is currently a lack of information regarding the potential cognitive consequences of the extended use of this technique. This work describes, for the first time, the cognitive outcomes after RFTC in patients with temporal lobe epilepsy (TLE), evaluated longitudinally and using a control group.
View Article and Find Full Text PDF